Related references
Note: Only part of the references are listed.MicroRNA-mediated autophagy regulation in cancer therapy: The role in chemoresistance/chemosensitivity
Milad Ashrafizadeh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Characterization ofTP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma
M. Herman Chui et al.
MODERN PATHOLOGY (2021)
Tumor-associated macrophage-targeted therapeutics in ovarian cancer
Yuanyuan An et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunothrapy
Sonia Iyer et al.
CANCER DISCOVERY (2021)
Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis
Yinu Wang et al.
CANCER RESEARCH (2021)
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
Shunfei Yan et al.
BRITISH JOURNAL OF CANCER (2021)
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Changxin Wan et al.
CANCER RESEARCH (2021)
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development
Gesuino Angius et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review
D. Huber et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis
Mingxin Shi et al.
BIOLOGY OF REPRODUCTION (2020)
EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition
Sergey Karakashev et al.
CANCER CELL (2020)
The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance
Isabella Giacomini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Richard T. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment
Min Ju Kim et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness
Sandra Munoz-Galvan et al.
MOLECULAR CANCER (2020)
Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy
Muhammad Kalim et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2020)
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
Patrycja Gralewska et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer
Marek Nowak et al.
CELLS (2020)
CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
Justin W. Gorski et al.
DIAGNOSTICS (2020)
Immunotherapy for platinum-resistant ovarian cancer
Giorgio Bogani et al.
GYNECOLOGIC ONCOLOGY (2020)
The Role of CDKs and CDKIs in Murine Development
Grace Jean Campbell et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2020)
Emerging roles of lamins and DNA damage repair mechanisms in ovarian cancer
Duhita Sengupta et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2020)
The tubal epigenome - An emerging target for ovarian cancer
Hunter D. Reavis et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim et al.
NATURE COMMUNICATIONS (2020)
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes
Antonella Pietragalla et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Metformin and ovarian cancer: the evidence
Elina Urpilainen et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
STAT3 signaling in ovarian cancer: a potential therapeutic target
Renba Liang et al.
JOURNAL OF CANCER (2020)
NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer
Alexander J. Cole et al.
JCI INSIGHT (2020)
PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers
Geraldine Gentric et al.
CELL METABOLISM (2019)
Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial
Mary L. Disis et al.
JAMA ONCOLOGY (2019)
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes
Alexandre A. B. A. da Costa et al.
BMC CANCER (2019)
A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
Hye Joung Choi et al.
GYNECOLOGIC ONCOLOGY (2019)
A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer
Nkechiyere G. Nwani et al.
CANCERS (2019)
Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression
Junli Deng et al.
BMC CANCER (2019)
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Laetitia Marzi et al.
CLINICAL CANCER RESEARCH (2019)
Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells
Markus Kleih et al.
CELL DEATH & DISEASE (2019)
Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review
Sudeep Gupta et al.
JOURNAL OF OVARIAN RESEARCH (2019)
Therapeutic Inducers of Apoptosis in Ovarian Cancer
Mudra Binju et al.
CANCERS (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Epigenetic therapy for ovarian cancer: promise and progress
Sara Moufarrij et al.
CLINICAL EPIGENETICS (2019)
Ovarian cancer stem cells and targeted therapy
Vahideh Keyvani et al.
JOURNAL OF OVARIAN RESEARCH (2019)
Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
Francesca Ricci et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Inhibition of autophagy initiation potentiates chemosensitivity in mesothelioma
Carlo Follo et al.
MOLECULAR CARCINOGENESIS (2018)
A panel of three oxidative stress-related genes predicts overall survival in ovarian cancer patients received platinum-based chemotherapy
Jin Zhang et al.
AGING-US (2018)
Autophagy in health and disease: A comprehensive review
Sarbari Saha et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
The Study of Nrf2 Signaling Pathway in Ovarian Cancer
Xiaotong Wu et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2018)
How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
Philippe Icard et al.
DRUG RESISTANCE UPDATES (2018)
Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism
Shan-Shan Li et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2018)
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
Jung-Min Lee et al.
LANCET ONCOLOGY (2018)
Inhibition of cancer stem cell like cells by a synthetic retinoid
Junwei Chen et al.
NATURE COMMUNICATIONS (2018)
DNA damage repair in ovarian cancer: unlocking the heterogeneity
Mary Ellen Gee et al.
JOURNAL OF OVARIAN RESEARCH (2018)
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer
Dong Hou et al.
REDOX BIOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Diagnosis and Treatment of Ovarian Cancer
Brian Orr et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
Yizhou Joseph He et al.
NATURE (2018)
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
Dale W. Garsed et al.
CLINICAL CANCER RESEARCH (2018)
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
George Au-Yeung et al.
CLINICAL CANCER RESEARCH (2017)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Benjamin G. Bitler et al.
NATURE CELL BIOLOGY (2017)
Cancer stem cells revisited
Eduard Batlle et al.
NATURE MEDICINE (2017)
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
Chaoyang Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
Ioannis K. Zervantonakis et al.
NATURE COMMUNICATIONS (2017)
Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions
Susan M. Domchek
CANCER DISCOVERY (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Purushottam Lamichhane et al.
CANCER RESEARCH (2017)
Acquired chemotherapy resistance in ovarian cancer
E. L. Christie et al.
ANNALS OF ONCOLOGY (2017)
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation
Alessandra Dall'Acqua et al.
EMBO MOLECULAR MEDICINE (2017)
Linking metabolic reprogramming to therapy resistance in cancer
Andrea Morandi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins
Isa N. Cruz et al.
CANCER GENOMICS & PROTEOMICS (2017)
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
M. Moschetta et al.
ANNALS OF ONCOLOGY (2016)
Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism
Zhihong Ai et al.
CANCER LETTERS (2016)
The cancer stem-cell signaling network and resistance to therapy
A. Carnero et al.
CANCER TREATMENT REVIEWS (2016)
Homologous recombination deficiency and ovarian cancer
Jonathan A. Ledermann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Stress management by autophagy: Implications for chemoresistance
Zhao Huang et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors (vol 22, pg 194, 2016)
Yi Du et al.
NATURE MEDICINE (2016)
Ovarian cancer
Ursula A. Matulonis et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy
Jun He et al.
AUTOPHAGY (2015)
Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy
Anna Shteingauz et al.
CANCER RESEARCH (2015)
Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor
David M. Gershenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
Rachel N. Grisham et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion
Monique G. P. van der Wijst et al.
MOLECULAR ONCOLOGY (2015)
OVARIAN CANCER: BEYOND RESISTANCE
David Holmes
NATURE (2015)
An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
D. M. Janzen et al.
NATURE COMMUNICATIONS (2015)
Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer
Tae Hun Kim et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance
Ethan B. Butler et al.
CANCER RESEARCH (2013)
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer
Meghan L. Verschoor et al.
MOLECULAR CANCER (2013)
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Dariush Etemadmoghadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Targeting cellular metabolism to improve cancer therapeutics
Y. Zhao et al.
CELL DEATH & DISEASE (2013)
Unravelling cancer stem cell potential
Benjamin Beck et al.
NATURE REVIEWS CANCER (2013)
Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
Edita Aksamitiene et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Tumor Cell Autophagy as an Adaptive Response Mediating Resistance to Treatments Such as Antiangiogenic Therapy
Yu-Long Hu et al.
CANCER RESEARCH (2012)
Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
Patricia M. LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response
Y. Zhang et al.
ONCOGENE (2012)
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak et al.
CANCER DISCOVERY (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers
Bin Guan et al.
CANCER RESEARCH (2011)
Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival
Ines A. Silva et al.
CANCER RESEARCH (2011)
Cancer Stem Cells and Chemosensitivity
Marcello Maugeri-Sacca et al.
CLINICAL CANCER RESEARCH (2011)
p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins
Huimei Yu et al.
EUROPEAN JOURNAL OF CANCER (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Adam Lister et al.
MOLECULAR CANCER (2011)
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
Robert L. Coleman et al.
LANCET ONCOLOGY (2011)
Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons
Jewel L. Podratz et al.
NEUROBIOLOGY OF DISEASE (2011)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Triona Ni Chonghaile et al.
SCIENCE (2011)
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant
L. Hu et al.
BRITISH JOURNAL OF CANCER (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting metabolic transformation for cancer therapy
Daniel A. Tennant et al.
NATURE REVIEWS CANCER (2010)
Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
Christina Gewinner et al.
CANCER CELL (2009)
Epigenetic regulation of CD133 and tumorigenicity of CD133+ovarian cancer cells
T. Baba et al.
ONCOGENE (2009)
Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells
Alex M. Chen et al.
SMALL (2009)
Identification and characterization of ovarian cancer-initiating cells from primary human tumors
Shu Zhang et al.
CANCER RESEARCH (2008)
Roles of p53, Myc and HIF-1 in Regulating Glycolysis - the Seventh Hallmark of Cancer
S. J. Yeung et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
The impact of T-cell immunity on ovarian cancer outcomes
Brad H. Nelson
IMMUNOLOGICAL REVIEWS (2008)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis
Zejia Yang et al.
CLINICAL CANCER RESEARCH (2006)
Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles
K Itoh et al.
FREE RADICAL BIOLOGY AND MEDICINE (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
M Baekelandt et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
C Lavarino et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
M Baekelandt et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
